The U.S. Customs and Border Protection has found that the redesigned Electrocardiography in the Apple Watch does not violate patents held by AliveCor, a medical device company. This ruling further complicates AliveCor’s legal challenges against Apple Inc. (NASDAQ:AAPL).
What Happened: The U.S. Customs and Border Protection has concluded that the redesigned ECG in the Apple Watch does not infringe on patents held by AliveCor. This decision means that the affected Apple Watch models are not subject to the International Trade Commission’s Limited Exclusion Order.
As a result, Apple can import these Apple Watch models into the U.S. for sale without having to pay a $2 bond for each unit. This ruling adds to AliveCor’s legal setbacks in its ongoing legal battle against Apple.
CBP’s filing stated, “We find that Apple has met its burden to establish that the articles at issue do not infringe any of claims 12, 13, and 19-23 of ...